Phenotype and molecular characterization of Wilson's disease in Morocco.

ATP7B gene Genotype Morocco Phenotype Prevalence Wilson's disease

Journal

Clinics and research in hepatology and gastroenterology
ISSN: 2210-741X
Titre abrégé: Clin Res Hepatol Gastroenterol
Pays: France
ID NLM: 101553659

Informations de publication

Date de publication:
06 Apr 2024
Historique:
received: 01 08 2022
revised: 29 01 2024
accepted: 29 03 2024
medline: 9 4 2024
pubmed: 9 4 2024
entrez: 8 4 2024
Statut: aheadofprint

Résumé

In Morocco the prevalence of Wilson disease (WD) and the spectrum of mutations are not known. The aim of the present study was to estimate the prevalence of WD in Morocco, to evaluate the phenotype among a large cohort of WD patients, and to characterize ATP7B variants in a subgroup of WD patients. We collected data from 226 patients admitted to five university hospital centers in Morocco between 2008 and 2020. The diagnosis was based on clinical manifestations, function tests and biochemical parameters. The genotype was characterized in 18 families diagnosed at the University Hospital Center of Marrakesh, by next generation sequencing. The mean annual prevalence in Morocco was 3.88 per 100,000 and the allele frequency was 0.15%. Among the 226 patients included (121 males and 105 females), 196 were referred for a hepatic or neurological involvement and 30 were asymptomatic. The mean age at diagnosis was 13 ± 5.1 years (range: 5 - 42 years). Consanguinity was found in 63.3% of patients. The mean duration of illness was 2.8 ± 1.9 years. Kayser-Fleischer rings were found in 131 (67.9%) of 193 patients. Among the 196 symptomatic patients, 141/159 (88.7%) had low serum ceruloplasmin (<0.2g/L) and a high 24-hours urinary copper (>100μg/day) was found in 173/182 (95.1%) patients. The initial treatment was D-penicillamine in 207 patients, zinc acetate in five, zinc sulphate in five, and nine patients were not treated; 60/207 (29%) patients have stopped treatment. A total of 72 patients died; the mortality rate was 31.9%. Eight different ATP7B variants were identified among the 18 patients studied, of which two were novel (p.Cys1104Arg and p.Gln1277Hisfs*52), and six previously published (p.Gln289Ter, p.Cys305Ter, p.Thr1232Pro, p.Lys1020Arg, p.Glu583ArgfsTer25 and c.51+4A>T). All informative patients were homozygous for the disease-causing mutation. In Morocco, a high prevalence due to consanguinity and a high mortality rate due to the difficulty of diagnosis and lack of treatment were observed in WD patients. NGS sequencing identified new ATP7B variants in WD patients from Morocco.

Sections du résumé

BACKGROUND AND STUDY AIMS OBJECTIVE
In Morocco the prevalence of Wilson disease (WD) and the spectrum of mutations are not known. The aim of the present study was to estimate the prevalence of WD in Morocco, to evaluate the phenotype among a large cohort of WD patients, and to characterize ATP7B variants in a subgroup of WD patients.
PATIENTS AND METHODS METHODS
We collected data from 226 patients admitted to five university hospital centers in Morocco between 2008 and 2020. The diagnosis was based on clinical manifestations, function tests and biochemical parameters. The genotype was characterized in 18 families diagnosed at the University Hospital Center of Marrakesh, by next generation sequencing.
RESULTS RESULTS
The mean annual prevalence in Morocco was 3.88 per 100,000 and the allele frequency was 0.15%. Among the 226 patients included (121 males and 105 females), 196 were referred for a hepatic or neurological involvement and 30 were asymptomatic. The mean age at diagnosis was 13 ± 5.1 years (range: 5 - 42 years). Consanguinity was found in 63.3% of patients. The mean duration of illness was 2.8 ± 1.9 years. Kayser-Fleischer rings were found in 131 (67.9%) of 193 patients. Among the 196 symptomatic patients, 141/159 (88.7%) had low serum ceruloplasmin (<0.2g/L) and a high 24-hours urinary copper (>100μg/day) was found in 173/182 (95.1%) patients. The initial treatment was D-penicillamine in 207 patients, zinc acetate in five, zinc sulphate in five, and nine patients were not treated; 60/207 (29%) patients have stopped treatment. A total of 72 patients died; the mortality rate was 31.9%. Eight different ATP7B variants were identified among the 18 patients studied, of which two were novel (p.Cys1104Arg and p.Gln1277Hisfs*52), and six previously published (p.Gln289Ter, p.Cys305Ter, p.Thr1232Pro, p.Lys1020Arg, p.Glu583ArgfsTer25 and c.51+4A>T). All informative patients were homozygous for the disease-causing mutation.
CONCLUSION CONCLUSIONS
In Morocco, a high prevalence due to consanguinity and a high mortality rate due to the difficulty of diagnosis and lack of treatment were observed in WD patients. NGS sequencing identified new ATP7B variants in WD patients from Morocco.

Identifiants

pubmed: 38588792
pii: S2210-7401(24)00056-1
doi: 10.1016/j.clinre.2024.102335
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102335

Informations de copyright

Copyright © 2024. Published by Elsevier Masson SAS.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: This work was supported by the Association pour le Développement de la Neurogénétique.

Auteurs

Nadia Abbassi (N)

Université Cadi Ayyad, Faculté des Sciences Semlalia, LHEAC, 40000, Marrakech, Maroc; Université Claude Bernard Lyon 1, INSERM-U1060, INRA, INSA, Laboratoire CarMeN, 69500, Lyon, France. Electronic address: nadiaabbassi3@gmail.com.

Aicha Bourrahouat (A)

Université Cadi Ayyad, Faculté de Médecine et de pharmacie, Laboratoire de recherche de l'enfance, la santé et le développement, 40000, Marrakech, Maroc; CHU Mohammed VI de Marrakech, Hôpital Mère-Enfant, Service de Pédiatrie, 40080, Marrakech, Maroc.

Eduardo Couchonnal Bedoya (EC)

HCL, Centre de référence de la maladie de Wilson, 69500, Lyon, France; HCL, Hôpital Mère-Femme-Enfant, Unité de Gastroentrologie, Hépatologie et Nutrition, 69500, Lyon, France.

Cécile Pagan (C)

HCL, Centre de Biochimie et Biologie Moléculaire, LBMMS, 69500, Lyon, France.

Meriem El Qabli (ME)

Université Cadi Ayyad, Faculté de Médecine et de pharmacie, Laboratoire de recherche de l'enfance, la santé et le développement, 40000, Marrakech, Maroc.

Sana Maidoumi (S)

Université Cadi Ayyad, Faculté des Sciences Semlalia, LHEAC, 40000, Marrakech, Maroc.

Abdelouahed Belmalih (A)

HCL, Centre de référence de la maladie de Wilson, 69500, Lyon, France.

Olivier Guillaud (O)

HCL, Hôpital Mère-Femme-Enfant, Unité de Gastroentrologie, Hépatologie et Nutrition, 69500, Lyon, France.

Najib Kissani (N)

CHU Mohammed VI de Marrakech, Hôpital Arrazi, Service de Neurologie, 40080, Marrakech, Maroc.

Abdelhak Abkari (A)

CHU Ibn Rochd de Casablanca, Hôpital Mère-Enfant, Service de Gastro-Pédiatrie, 20360, Casablanca, Maroc.

Imane Chahid (I)

CHU Ibn Rochd de Casablanca, Hôpital Mère-Enfant, Service de Gastro-Pédiatrie, 20360, Casablanca, Maroc.

Mohammed Abdoh Rafai (MA)

CHU Ibn Rochd de Casablanca, Service de Neurologie adulte, 20360, Casablanca, Maroc.

Nezha Mouane (N)

CHU Ibn Sina de Rabat, Hôpital Mère-Enfant, Service de Gastro-Pédiatrie, 10100, Rabat, Maroc.

Yamna Kriouile (Y)

CHU Ibn Sina de Rabat, Hôpital Mère-Enfant, Service de Gastro-Pédiatrie, 10100, Rabat, Maroc.

Saadia Aidi (S)

CHU Ibn Sina de Rabat, Service de Neurologie adulte, 10100 Rabat, Maroc.

Moustpha Hida (M)

CHU Hassan II de Fès, Hôpital Mère-Enfant, Service de Pédiatrie, 30050 Fès, Maroc.

Mounia Lakhdar Idrissi (ML)

CHU Hassan II de Fès, Hôpital Mère-Enfant, Service de Pédiatrie, 30050 Fès, Maroc.

Mohammed Faouzi Belahsen (MF)

CHU Hassan II de Fès, Service de Neurologie adulte, 30050, Fès, Maroc.

Mohammed El Abkari (ME)

CHU Hassan II de Fès, Service de Gastroenterologie et Hépatologie adulte, 30050 Fès, Maroc.

Maria Rkain (M)

CHU Mohammed VI d'Oujda, Hôpital Mère-Enfant, Service de Pédiatrie, 60049 Oujda, Maroc.

Zahi Ismaili (Z)

CHU Mohammed VI d'Oujda, Service de Gastroenterologie et Hépatologie adulte, 60049, Oujda, Maroc.

Azeddine Sedki (A)

Université Cadi Ayyad, Faculté des Sciences Semlalia, LHEAC, 40000, Marrakech, Maroc.

Muriel Bost (M)

HCL, Centre de référence de la maladie de Wilson, 69500, Lyon, France; HCL, Centre de Biochimie et Biologie Moléculaire, LBMMS, 69500, Lyon, France.

Nisrine Aboussair (N)

Université Cadi Ayyad, Faculté de Médecine et de pharmacie, Laboratoire de recherche de l'enfance, la santé et le développement, 40000, Marrakech, Maroc; CHU Mohammed VI de Marrakech, Centre de recherche clinique, Service de Génétique, 40080, Marrakech, Maroc.

Alain Lachaux (A)

HCL, Centre de référence de la maladie de Wilson, 69500, Lyon, France; HCL, Hôpital Mère-Femme-Enfant, Unité de Gastroentrologie, Hépatologie et Nutrition, 69500, Lyon, France; Université Claude Bernard Lyon 1, CIRI-INSERM-U1111, CNRS UMR5308, 69100, Lyon, France.

Classifications MeSH